Trial · NCT07903740
Effects of Combined Pericapsular Nerve Group (PENG) and Lateral Femoral Cutaneous Nerve (LFCN) Blocks on Anaesthetic Requirements and Electroencephalographic Depth of Anaesthesia During Total Hip Arthroplasty
NCT07903740, Not applicable, Not yet recruiting, Kocaeli City Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Combined Pericapsular Nerve Group (PENG) and Lateral Femoral Cutaneous Nerve (LFCN) Blocks on Anaesthetic Requirements and Electroencephalographic Depth of Anaesthesia During Total Hip Arthroplasty. Trials, record NCT07903740. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903740
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Effects of Combined Pericapsular Nerve Group (PENG) and Lateral Femoral Cutaneous Nerve (LFCN) Blocks on Anaesthetic Requirements and Electroencephalographic Depth of Anaesthesia During Total Hip Arthroplasty
- NCT number
- NCT07903740
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Kocaeli City Hospital
- Conditions
- Total Hip Arthroplasty (THA)
- Interventions
- Combined Pericapsular Nerve Group (PENG) and Lateral Femoral Cutaneous Nerve (LFCN) Block, EEG-Guided General Anaesthesia
- First posted
- 2026-10-29
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Intraoperative Sevoflurane Consumption (ml/h) | From initiation of sevoflurane administration after tracheal intubation until discontinuation of sevoflurane at the end of surgery. | Intraoperative sevoflurane consumption will be recorded in millilitres (mL) using the anaesthesia workstation. Hourly sevoflurane consumption will be calculated by dividing the total consumption by the duration of sevoflurane administration in hours. |
| Secondary | Weight-Adjusted Intraoperative Remifentanil Consumption (µg/kg/h) | From initiation to discontinuation of remifentanil infusion during general anaesthesia. | Weight-adjusted hourly remifentanil consumption will be determined by dividing the total administered remifentanil dose (µg) by patient body weight (kg) and the duration of remifentanil infusion in hours. |
| Secondary | Mean Intraoperative Patient State Index (PSI) | From initiation of sevoflurane administration after tracheal intubation until discontinuation of sevoflurane at the end of surgery. | The mean Patient State Index (PSI) during sevoflurane anaesthesia will be determined using continuous EEG monitoring data obtained from the SedLine system. |
| Secondary | Mean Intraoperative Suppression Ratio (SR) | From initiation of sevoflurane administration after tracheal intubation until discontinuation of sevoflurane at the end of surgery. | The mean suppression ratio (SR) will be determined using continuous EEG monitoring data obtained from the SedLine system during sevoflurane anaesthesia and expressed as a percentage (%). |
| Secondary | Percentage of Time With Suppression Ratio Above 5% | From initiation of sevoflurane administration after tracheal intubation until discontinuation of sevoflurane at the end of surgery. | The percentage of time during which the suppression ratio (SR) exceeds 5% will be determined using continuous EEG monitoring data obtained from the SedLine system during sevoflurane anaesthesia. |
| Secondary | Time to Extubation (min) | From discontinuation of sevoflurane administration until tracheal extubation. | Time to extubation will be defined as the interval between discontinuation of sevoflurane administration and removal of the endotracheal tube, expressed in minutes. |
| Secondary | Postoperative Richmond Agitation-Sedation Scale (RASS) Score | At 10, 15, 30, and 45 minutes after admission to the post-anaesthesia care unit (PACU). | Postoperative sedation and agitation will be assessed using the Richmond Agitation-Sedation Scale (RASS) at 10, 15, 30, and 45 minutes after admission to the post-anaesthesia care unit (PACU). Scores range from -5 (unarousable) to +4 (combative), with 0 indicating an alert and calm state. |
| Secondary | Postoperative Nursing Delirium Screening Scale (NuDESC) Score | At 10, 15, 30, and 45 minutes after admission to the post-anaesthesia care unit (PACU). | Postoperative delirium-related symptoms will be assessed using the Nursing Delirium Screening Scale (NuDESC) at 10, 15, 30, and 45 minutes after admission to the post-anaesthesia care unit (PACU). Scores range from 0 to 10, with higher scores indicating more pronounced delirium-related symptoms. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903740
GET https://conductscience.org/api/trials/v1/NCT07903740/registered